Literature DB >> 8244254

Persistence of hepatitis B virus DNA in the liver after loss of HBsAg in chronic hepatitis B.

T L Fong1, A M Di Bisceglie, M A Gerber, J G Waggoner, J H Hoofnagle.   

Abstract

To determine whether patients with chronic hepatitis B who lose hepatitis B virus DNA and HBsAg from the serum completely resolve the hepatitis and virus infection, we evaluated serum and liver tissue from 11 patients who had lost HBsAg. These patients were evaluated for clinical, histological and serological features and for hepatitis B virus DNA by use of hybridization and polymerase chain reaction techniques. Liver biochemical test results were normal in all except two patients who had mild aminotransferase elevations. All sera were negative for hepatitis B virus DNA by direct hybridization, and only one was positive transiently by polymerase chain reaction. Liver histology was abnormal in all patients, but the changes were mild and markedly improved compared with biopsy specimens taken before loss of HBsAg. Liver tissue from 10 patients was positive for hepatitis B virus DNA by polymerase chain reaction but not by direct hybridization. These findings indicate that loss of HBsAg is associated with marked improvements in clinical and serum biochemical features of chronic hepatitis B, yet mild degrees of hepatitis and low levels of viral DNA may persist in the liver.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8244254

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  23 in total

Review 1.  Diagnosis and management of clinical and subclinical cobalamin deficiency: advances and controversies.

Authors:  Ralph Carmel; Mona Sarrai
Journal:  Curr Hematol Rep       Date:  2006-03

Review 2.  Management of patients with hepatitis B who require immunosuppressive therapy.

Authors:  Jessica P Hwang; Anna S-F Lok
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-11-19       Impact factor: 46.802

Review 3.  Natural regression of fibrosis in chronic hepatitis B.

Authors:  Shogo Ohkoshi; Haruka Hirono; Kazuhiko Watanabe; Katsuhiko Hasegawa; Kenya Kamimura; Masahiko Yano
Journal:  World J Gastroenterol       Date:  2016-06-28       Impact factor: 5.742

4.  Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management.

Authors:  Chun-Jen Liu; Pei-Jer Chen; Ding-Shinn Chen; Jia-Horng Kao
Journal:  Hepatol Int       Date:  2011-06-14       Impact factor: 6.047

5.  Previous or occult hepatitis B virus infection in hepatitis C virus-associated hepatocellular carcinoma without hepatic fibrosis.

Authors:  S Kubo; A Tamori; K Ohba; T Shuto; T Yamamoto; H Tanaka; S Nishiguchi; K Wakasa; K Hirohashi; H Kinoshita
Journal:  Dig Dis Sci       Date:  2001-11       Impact factor: 3.199

6.  Persistence of hepatic hepatitis B virus after serological clearance of HBsAg with autologous peripheral stem cell transplantation.

Authors:  G K Lau; P C Wu; R Liang; S T Yuen; W L Lim
Journal:  J Clin Pathol       Date:  1997-08       Impact factor: 3.411

Review 7.  Natural course, therapeutic options and economic evaluation of therapies for chronic hepatitis B.

Authors:  Steven-Huy B Han
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 8.  Prevention of hepatitis B virus reactivation in immunosuppressive therapy or chemotherapy.

Authors:  Waka Ohishi; Kazuaki Chayama
Journal:  Clin Exp Nephrol       Date:  2011-06-01       Impact factor: 2.801

9.  Durability of Spontaneous and Treatment-Related Loss of Hepatitis B s Antigen.

Authors:  Ahmad Samer Alawad; Sungyoung Auh; Daniel Suarez; Marc G Ghany
Journal:  Clin Gastroenterol Hepatol       Date:  2019-07-16       Impact factor: 11.382

10.  Serum Mac-2-binding protein (M2BPGi) as a marker of chronological liver fibrosis in biliary atresia patients with cirrhosis.

Authors:  Takehisa Ueno; Tasuku Kodama; Yuki Noguchi; Motonari Nomura; Ryuta Saka; Yuichi Takama; Yuko Tazuke; Kazuhiko Bessho; Hiroomi Okuyama
Journal:  Pediatr Surg Int       Date:  2019-08-07       Impact factor: 1.827

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.